Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
10h
Hosted on MSNWe Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug WarsShares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 ...
Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...
Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co. (NYSE:LLY), disclosed the sale of shares worth approximately $183.6 million, according to recent filings. The transactions, which ...
Eli Lilly, BCE, Suncor, Canada Goose, Bombardier, Thomson Reuters and Lightspeed reported earnings this week. Here are the details for Canadian investors.
Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...
It can be hard to sate investors’ appetites, but if there’s two companies who should know how to do it, it’s these two.
While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.
Kismet, an English Springer Spaniel, and her owner Stacey Yeoman have been bringing joy to patients and staff at Novant Health Mint Hill Medical Center for the past two months as a therapy dog team.
Improvements include portions of Elizabeth, 29th, and Court Streets, along with most of Bonforte Boulevard. Work should start ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results